CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc., presented positive data from the FORESEE trial on November 22, 2024, at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting. The trial showcased the CNSide Cerebrospinal Fluid (CSF) Assay Platform's utility.
The prospective FORESEE trial met its key primary and secondary endpoints, demonstrating that the CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases. The assay also showed 2.8 times the diagnostic sensitivity compared to standard cytology.
These results indicate that CNSide may be a valuable tool for accurately identifying LM patients, ruling out at-risk individuals, and enhancing disease management and monitoring. This addresses a critical diagnostic gap where standard CSF cytology lacks sufficient sensitivity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.